Placeholder Banner

BIO Comments on FDA Draft Guidance on Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment

October 8, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment.

The draft guidance is an important step in clarifying the FDA’s view of endpoints to demonstrate efficacy of therapies to treat opioid use disorder (OUD). It’s important to expand primary and secondary endpoints in clinical trials for medications to treat opioid use disorder, including the outcomes patients and clinicians said were important to them at the public meeting on patient-focused drug development for opioid use disorder.

BIO requests clarification on how the FDA defines relapse to illicit opioid use, and requests FDA consider other possible endpoints to demonstrate effectiveness of drugs. BIO recommends the FDA provide additional detail on Phase III studies for medication assisted treatments.

Download Full Comments Below
BIO Comment Letter Opioid Use Disorder Endpoints For Demonstrating Effectiveness Of Drugs For Medication-Assisted Treatment FDA-2018-D-2382
Read full comment letter below
Discover More
The undersigned food, agriculture, and seafood trade associations respectfully urge the expeditious nomination of the Chief Agricultural Negotiator at the Office of the U.S. Trade Representative. America’s farmers, ranchers, processors, exporters…
The undersigned trade associations and private sector organizations write to express our strong support for the Endless Frontier Act, sponsored by Senate Majority Chuck Schumer (D-NY) and Senator Todd Young (R-IN), which would provide much needed,…
Dr. Michelle McMurry-Heath, along with a group of business and policy leaders, sends an open letter to President Biden urging him "to demonstrate decisive U.S. leadership" to combat COVID-19 in Latin America, Europe, Asia, and Africa…